Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury

K. Araki, A. Shiotani, K. Watabe, K. Saito, K. Moro, Kaoru Ogawa

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

To assess the possibility of gene therapy for recurrent laryngeal nerve (RLN) injury, we examined functional and histological recovery after glial cell line-derived neurotrophic factor (GDNF) gene transfer in a rat RLN crush model. Adenoviral vector encoding β-galactosidase gene (AxCALacZ) or human GDNF gene (AxCAhGDNF) was injected into the crush site of the RLN. Neurons in the nucleus ambiguus on the crushed side were labeled with X-gal or GDNF immnohistochemistry after AxCALacZ or AxCAhGDNF injection. Reverse transcription-polymerase chain reaction analysis revealed expression of human GDNF mRNA transcripts in brainstem tissue containing the nucleus ambiguus on the crushed side after AxCAhGDNF injection. Animals injected with AxCAhGDNF displayed significantly improved motor nerve conduction velocity of the RLN and recovery rate of vocal fold movement at 2 and 4 weeks after treatment as compared to controls. AxCAhGDNF-injected animals showed a significantly larger axonal diameter and improved remyelination in crushed RLN as compared to controls. Adenoviral GDNF gene transfer may thus promote laryngeal function recovery after RLN injury. Inoculation of adenoviral vector containing the GDNF gene at the site of damage soon after nerve injury may assist patients with laryngeal paralysis caused by nerve injury during head and neck surgery.

Original languageEnglish
Pages (from-to)296-303
Number of pages8
JournalGene Therapy
Volume13
Issue number4
DOIs
Publication statusPublished - 2006 Feb

Fingerprint

Recurrent Laryngeal Nerve Injuries
Glial Cell Line-Derived Neurotrophic Factor
Recurrent Laryngeal Nerve
Genes
Medulla Oblongata
Galactosidases
Nerve Crush
Neck Injuries
Vocal Cord Paralysis
Injections
Vocal Cords
Neural Conduction
Recovery of Function
Craniocerebral Trauma
Genetic Therapy
Brain Stem
Reverse Transcription

Keywords

  • Adenovirus
  • Cranial nerve injury
  • GDNF
  • Nucleus ambiguus
  • Recurrent laryngeal nerve
  • Vocal fold palsy

ASJC Scopus subject areas

  • Genetics

Cite this

Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury. / Araki, K.; Shiotani, A.; Watabe, K.; Saito, K.; Moro, K.; Ogawa, Kaoru.

In: Gene Therapy, Vol. 13, No. 4, 02.2006, p. 296-303.

Research output: Contribution to journalArticle

Araki, K. ; Shiotani, A. ; Watabe, K. ; Saito, K. ; Moro, K. ; Ogawa, Kaoru. / Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury. In: Gene Therapy. 2006 ; Vol. 13, No. 4. pp. 296-303.
@article{3bf80484017241be9650b470b7c28a01,
title = "Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury",
abstract = "To assess the possibility of gene therapy for recurrent laryngeal nerve (RLN) injury, we examined functional and histological recovery after glial cell line-derived neurotrophic factor (GDNF) gene transfer in a rat RLN crush model. Adenoviral vector encoding β-galactosidase gene (AxCALacZ) or human GDNF gene (AxCAhGDNF) was injected into the crush site of the RLN. Neurons in the nucleus ambiguus on the crushed side were labeled with X-gal or GDNF immnohistochemistry after AxCALacZ or AxCAhGDNF injection. Reverse transcription-polymerase chain reaction analysis revealed expression of human GDNF mRNA transcripts in brainstem tissue containing the nucleus ambiguus on the crushed side after AxCAhGDNF injection. Animals injected with AxCAhGDNF displayed significantly improved motor nerve conduction velocity of the RLN and recovery rate of vocal fold movement at 2 and 4 weeks after treatment as compared to controls. AxCAhGDNF-injected animals showed a significantly larger axonal diameter and improved remyelination in crushed RLN as compared to controls. Adenoviral GDNF gene transfer may thus promote laryngeal function recovery after RLN injury. Inoculation of adenoviral vector containing the GDNF gene at the site of damage soon after nerve injury may assist patients with laryngeal paralysis caused by nerve injury during head and neck surgery.",
keywords = "Adenovirus, Cranial nerve injury, GDNF, Nucleus ambiguus, Recurrent laryngeal nerve, Vocal fold palsy",
author = "K. Araki and A. Shiotani and K. Watabe and K. Saito and K. Moro and Kaoru Ogawa",
year = "2006",
month = "2",
doi = "10.1038/sj.gt.3302665",
language = "English",
volume = "13",
pages = "296--303",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury

AU - Araki, K.

AU - Shiotani, A.

AU - Watabe, K.

AU - Saito, K.

AU - Moro, K.

AU - Ogawa, Kaoru

PY - 2006/2

Y1 - 2006/2

N2 - To assess the possibility of gene therapy for recurrent laryngeal nerve (RLN) injury, we examined functional and histological recovery after glial cell line-derived neurotrophic factor (GDNF) gene transfer in a rat RLN crush model. Adenoviral vector encoding β-galactosidase gene (AxCALacZ) or human GDNF gene (AxCAhGDNF) was injected into the crush site of the RLN. Neurons in the nucleus ambiguus on the crushed side were labeled with X-gal or GDNF immnohistochemistry after AxCALacZ or AxCAhGDNF injection. Reverse transcription-polymerase chain reaction analysis revealed expression of human GDNF mRNA transcripts in brainstem tissue containing the nucleus ambiguus on the crushed side after AxCAhGDNF injection. Animals injected with AxCAhGDNF displayed significantly improved motor nerve conduction velocity of the RLN and recovery rate of vocal fold movement at 2 and 4 weeks after treatment as compared to controls. AxCAhGDNF-injected animals showed a significantly larger axonal diameter and improved remyelination in crushed RLN as compared to controls. Adenoviral GDNF gene transfer may thus promote laryngeal function recovery after RLN injury. Inoculation of adenoviral vector containing the GDNF gene at the site of damage soon after nerve injury may assist patients with laryngeal paralysis caused by nerve injury during head and neck surgery.

AB - To assess the possibility of gene therapy for recurrent laryngeal nerve (RLN) injury, we examined functional and histological recovery after glial cell line-derived neurotrophic factor (GDNF) gene transfer in a rat RLN crush model. Adenoviral vector encoding β-galactosidase gene (AxCALacZ) or human GDNF gene (AxCAhGDNF) was injected into the crush site of the RLN. Neurons in the nucleus ambiguus on the crushed side were labeled with X-gal or GDNF immnohistochemistry after AxCALacZ or AxCAhGDNF injection. Reverse transcription-polymerase chain reaction analysis revealed expression of human GDNF mRNA transcripts in brainstem tissue containing the nucleus ambiguus on the crushed side after AxCAhGDNF injection. Animals injected with AxCAhGDNF displayed significantly improved motor nerve conduction velocity of the RLN and recovery rate of vocal fold movement at 2 and 4 weeks after treatment as compared to controls. AxCAhGDNF-injected animals showed a significantly larger axonal diameter and improved remyelination in crushed RLN as compared to controls. Adenoviral GDNF gene transfer may thus promote laryngeal function recovery after RLN injury. Inoculation of adenoviral vector containing the GDNF gene at the site of damage soon after nerve injury may assist patients with laryngeal paralysis caused by nerve injury during head and neck surgery.

KW - Adenovirus

KW - Cranial nerve injury

KW - GDNF

KW - Nucleus ambiguus

KW - Recurrent laryngeal nerve

KW - Vocal fold palsy

UR - http://www.scopus.com/inward/record.url?scp=32444438913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32444438913&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302665

DO - 10.1038/sj.gt.3302665

M3 - Article

C2 - 16251996

AN - SCOPUS:32444438913

VL - 13

SP - 296

EP - 303

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 4

ER -